Navigation Links
Cerecor Raises $22 Million Series A Financing
Date:4/4/2012

BALTIMORE, April 4, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, announced today that it has raised over US$22 million in an overallotment of its January 2012 Series A preferred stock financing. The offering, which was placed with accredited investors including members of Cerecor's Board of Directors, significantly exceeded the offering maximum of US$15 million.  Maxim Group, LLC of New York, NY acted as placement agent in connection with the offering.

(Logo: http://photos.prnewswire.com/prnh/20120404/PH82224LOGO )

"The completion of this financing is an important step in bringing our lead product, FP01 for the treatment of chronic and acute cough, to the market and to support our early preclinical efforts in cognition and schizophrenia. We are delighted by the enthusiastic response to our offering, as it confirms the quality of our Company, its product pipeline and our founding team," stated Blake M. Paterson, M.D., Co-founder & CEO of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization.

SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
5. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
6. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
7. Creabilis Raises €15M ($20M) in Series B Fundraising Round
8. SironRX Therapeutics Raises $3.4 Million Series A
9. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
10. Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign
11. FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... PARIS and KYOTO, Japan, Oct. 25 Cellectis (Alternext: ... for iPS Cells Research and Application (CiRA) of Kyoto ... started a scientific collaboration to combine Cellectis, genome engineering ... to improve the natural characteristics of iPS cells for ...
... PITTSBURGH, Oct. 22 Mylan Inc. (Nasdaq: MYL ... have awarded a collective $1.25 million to support two prominent ... Arts and Sciences of West Virginia and the State of ... Bresch, Mylan,s president and a member of Mylan Charitable Foundation,s ...
... 700 Companies With 1.400 Participants Attend BioSpain 2010 -- MADRID, October 22, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
Cached Biology Technology:Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 2Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 3Mylan and Mylan Charitable Foundation Award a Collective $1.25 Million to Prominent West Virginia Cultural Institutions 2700 Companies With 1.400 Participants Attend BioSpain 2010 2700 Companies With 1.400 Participants Attend BioSpain 2010 3700 Companies With 1.400 Participants Attend BioSpain 2010 4700 Companies With 1.400 Participants Attend BioSpain 2010 5700 Companies With 1.400 Participants Attend BioSpain 2010 6700 Companies With 1.400 Participants Attend BioSpain 2010 7
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Sensor Market 2015-2019" report to their offering. ... major trend upcoming in this market is the increasing ... help in recording of patient data for quick and ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... 23, 2011 Employing technology that reads the entire ... Institute (TGen) and the Technical University of Denmark (DTU) ... Haiti that killed more than 6,000 people and sickened ... the billions of chemical bases in DNA, TGen and ...
... have discovered that bacteria like E. coli and Salmonella have ... to boost their chances for infection. It,s a fascinating ... the Aug. 14 issue of Nature Chemical Biology. ... and their proteins to gain strength. ,The team includes ...
... -- Aug. 22, 2011 -- Researchers at the Joslin Diabetes ... of cells is decreased in the skeletal muscle of those ... of drugs to boost the activity of this enzyme in ... published online today in the Proceedings of the National Academy ...
Cached Biology News:TGen and DTU researchers track source of Haitian cholera outbreak 2TGen and DTU researchers track source of Haitian cholera outbreak 3Newfound hijacked proteins linked to salmonella virulence 2Joslin researchers identify new target for treatment of type 2 diabetes and prediabetes 2